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Population Health Impact and Cost-Effectiveness
of Community-Supported Agriculture Among
Low-Income US Adults: A Microsimulation Analysis
Sanjay Basu, MD, PhD, Jessica O’Neill, Edward Sayer, PsyD, Maegan Petrie, BA, Rochelle Bellin, BA, and Seth A. Berkowitz, MD, MPH
Objectives. To estimate the population-level effectiveness and cost-effectiveness of a
subsidized community-supported agriculture (CSA) intervention in the United States.
Methods. In 2019, we developed a microsimulation model from nationally repre-
sentative demographic, biomedical, and dietary data (National Health and Nutrition
Examination Survey, 2013–2016) and a community-based randomized trial (conducted in
Massachusetts from 2017 to 2018). We modeled 2 interventions: unconditional cash
transfer ($300/year) and subsidized CSA ($300/year subsidy).
Results. The total discounted disability-adjusted life years (DALYs) accumulated over
the life course to cardiovascular disease and diabetes complications would be reduced
from24797per 10 000people (95%confidence interval [CI] = 24 584, 25 001) at baseline
to 23463 per 10 000 (95% CI = 23241, 23 666) under the cash intervention and 22 304
per 10 000 (95% CI = 22 084, 22 510) under the CSA intervention. From a societal per-
spective and over a life-course time horizon, the interventions had negative incremental
cost-effectiveness ratios, implying cost savings to society of –$191 100 perDALY averted
(95% CI = –$191767, –$188919) for the cash intervention and –$93182 per DALY
averted (95% CI = –$93707, –$92 503) for the CSA intervention.
Conclusions.Both the cash transfer and subsidizedCSAmaybe important public health
interventions for low-income persons in the United States. (Am J Public Health. 2020;
110:119–126. doi:10.2105/AJPH.2019.305364)
Diet-related disease is a major cause ofmorbidity and premature mortality in
1
participants drawn from a federally qualified
community health center over a 2-year pe-
riod.12 Improvements in diet quality are
linked to substantially lower cardiovascular
morbidity and mortality.13–18 Mechanisti-
cally, increasing fruit and vegetable intake
appears to reduce consumption of sodium,
increase consumption of potassium, and re-
duce peripheral insulin resistance.19–22 How-
ever, because the effect of improved diet
quality on health outcomes may only become
apparent over long time horizons, it is difficult
to study in the context of a randomized trial.
This argues for the use of microsimulation
modeling to inform policy by estimating
the population-level changes that may occur
with sustained intervention.
Here, we assessed the potential effective-
ness and cost-effectiveness (fromboth a health
care and societal perspective) of a CSA in-
tervention among low-income US adults by
using a nationally representative simulation
model. We tested our a priori hypothesis
that the CSA intervention would be more
cost-effective than providing the equivalent
value in cash.
METHODS
We designed an individual-level micro-
simulation model for the analysis. A micro-
simulation model samples from survey data
to capture the covariance of key input pa-
rameters (e.g., the correlation between
demographics, nutrition profile, health bio-
markers, and disease incidence), as opposed
to Markov cohort models that focus on pop-
ulation averages.23 Hence, microsimulation
models are useful for identifying intervention
impacts for populations affected by multiple
simultaneous risk factors and comorbidities.24,25
In the microsimulation (Appendix, Figure
A, available as a supplement to the online
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the United States and disproportionately affects 
individuals with lower socioeconomic status.2,3 
For this reason, interventions to improve diet 
quality in individuals with lower socioeco-
nomic status are a public health priority. Food 
insecurity, inadequate or uncertain access to 
nutritious food as a result of cost, is thought to be 
a major source of these disparities,4,5 as the 
perceived or real price of fruits and vegetables 
remains a barrier to increased intake.6–10
One strategy for improving diet quality is 
community-supported agriculture (CSA).11 
In the CSA model, individuals purchase a 
“share” of a farm’s produce in advance of the 
growing season and then receive weekly al-
lotments throughout the season. A recent 
randomized clinical trial found that a CSA 
was effective in improving diet quality for
participants with body mass index greater
than 25 kilograms divided by the square of
height in meters who either had household
income less than 200% of the federal poverty
level when adjusted for household size or
were Medicaid beneficiaries (or both),
resulting in an unweighted sample of
n = 73 248 (representing a weighted 121.9
million individuals).
Appendix, Table B compares demo-
graphic and clinical characteristics of the
NHANES and trial samples. We obtained
micronutrients and macronutrients in grams
or kilocalories per person per day by sam-
pling from two 24-hour dietary recalls in
NHANES, from which we calculated the
Healthy Eating Index (HEI) score (version
2015) by using a previously published ap-
proach.30 We obtained an individual’s bio-
medical profile by sampling from NHANES
survey, examination, and laboratory data.We
input these data into the revised Pooled
Cohort Equations for atherosclerotic car-
diovascular disease to predict 10-year and
life-course risk of myocardial infarction or
stroke26 (Appendix, Table C) and into the
RECODe equations (Risk Equations for
Complications of type 2 Diabetes) to estimate
risk of diabetes-contingent complications
(including myocardial infarction and stroke,
retinopathy, nephropathy, and neuropathy;
Appendix, Table D).27,28
Both sets of equations have been pre-
viously validated against diverse, longitudinal
US cohort data sets.26,28 We estimated di-
abetes incidence and life-course years
remaining (by age, sex, and race/ethnicity)
by sampling fromCenters for Disease Control
and Prevention data.31,32 We updated indi-
vidual covariates with each passing year
based on the risk of outcome and mortality
with that outcome and with a linear secular
trend by age and sex.
Postintervention Risk
We simulated 2 interventions: (1) pro-
vision of $300 per person per year in cash,
with guidance about healthy eating given at
the time of provision but no restrictions on
how the money was used or (2) provision of a
$300-person-per-year subsidy used to pur-
chase a CSA share. We selected these in-
terventions for simulation because there
are randomized trial data relating these
interventions to changes in diet quality, and
cost-effectiveness analysis for these strategies
had not previously been performed. In the
CSA intervention, individuals received a
weekly share of farm produce during the
6-month growing season (June to Novem-
ber), along with information about how to
use the produce and examples of healthy
recipes. For the main simulation, we simu-
lated intervention participation at 100%, and
we conducted sensitivity analyses to reflect
various reduced levels of participation.
In a previous randomized trial,12 the cash
intervention was observed to produce a 7%
(95% confidence interval [CI] = 3%, 11%)
increase in HEI score, and the CSA in-
tervention was observed to produce a 13%
(95% CI= 9%, 17%) increase in HEI score.
We used these effect sizes (without subgroup
analysis) to estimate how much the change in
diet quality attributable to each intervention
would be expected to change each of the
disease outcome endpoints. As the trial results
were estimated at the individual person level,
we incorporated them directly into the
individual-level effect size estimates for sim-
ulated persons. Specifically, we reviewed the
literature to find randomized trials (when
available) or prospective cohort studies that
examined how the change in diet quality
reflected by any of 4 validated diet quality
indices (HEI, Alternative Healthy Eating
Index, Dietary Approaches to Stop Hyper-
tension, and Mediterranean Diet Score)
corresponded to a change in each outcome,
averaging across all available information, and
converted to a 10% increase in diet quality
index.13–16,33,34
Cost-Effectiveness Analysis
We computed the DALYs accumulated
and dollars expended under the baseline, cash,
and CSA intervention scenarios. We defined
DALYs as the years of life lost from the disease
plus the years of life livedwith disability (years
weighted by a disutility weight reflecting the
degree of loss of life quality from the disease).
Following current cost-effectiveness guide-
lines,35,36 we computed these outcomes on
both a 10-year policy time horizon and from a
life-course perspective, as well as from both a
health care perspective and a societal per-
spective (see Appendix, Table E for Con-
solidated Health Economic Evaluation
version of this article at http://www.ajph. 
org), we constructed a simulated US pop-
ulation with demographic features of age, sex, 
and race/ethnicity (non-Hispanic White, 
non-Hispanic Black, Hispanic/Latino, or 
other). We sampled repeatedly from survey 
data described in the Baseline Risk section to 
simulate the typical distribution of key health 
variables including current nutrition and 
biomedical profile; because both the de-
mographic and health data were from the 
National Health and Nutrition Examination 
Survey (NHANES), both were considered 
population representative.
We then used validated risk equations—
one for the risk of atherosclerotic cardiovas-
cular disease events (myocardial infarction or 
stroke)26 and one for type 2 diabetes mellitus 
and its microvascular complications (ne-
phropathy, neuropathy, and retinopathy), as 
well as all-cause mortality27,28—to estimate 
the 10-year and life-course risk of cardio-
vascular and metabolic disease events. We 
then examined how much these cardiovas-
cular and metabolic disease event rates would 
be expected to change if individuals were 
provided $300 per year in cash or a $300-per-
year subsidy to be used to purchase a CSA 
share. The effect estimates were based on 
a trial in Massachusetts (NCT03231592), 
which provided $300 a year to participate. 
Those in the intervention group were re-
quired to purchase a CSA share. The CSA 
share entitled participants to once weekly 
produce pick up over 24 weeks (from June to 
November of a given year). The cost of the 
CSA share did not vary by age. Adults (aged 
‡ 18 years) were eligible to participate.
Baseline Risk
The data sources and input parameters 
are summarized in Appendix, Table A. We 
generated a simulation of the civilian, non-
institutionalized US population by sampling 
weighted data from the latest 2 cycles (2013–
2016) of NHANES.29 We drew the ran-
domized trial sample from participants at a 
federally qualified health center (and the 
surrounding low-income county) with body 
mass index greater than 25 kilograms divided 
by the square of height in meters. To emulate 
the lower socioeconomic status population 
this type of intervention might be applied 
to, our simulation included NHANES
changing diet quality the CSA intervention
would need to be, compared with the cash
intervention, to achieve the same ICER
when taking account of the higher overhead
rate of the CSA intervention. Third, we es-
timated how much less costly the CSA in-
tervention would need to be to achieve the
same ICER as the cash intervention when
taking account of the greater effectiveness of
the CSA. Fourth, we estimated the ICER if
the intervention only produced behavior
change for the initial year of intervention,
followed by reversion to baseline pre-
intervention dietary quality.
Finally, across all simulations, we per-
formed probabilistic sensitivity analysis by
Monte Carlo sampling 10 000 times from
Gaussian distributions constructed around
the mean and 95% CIs around all input
parameters to estimate the distribution
around each outcome metric and to plot the
cost-effectiveness plane. Input data and
statistical code for reproduction of the ana-
lyses are available at https://github.com/
sanjaybasu/CSA.
RESULTS
The included, unweighted NHANES
study sample had a mean age of 58.1 years
(interquartile range [IQR]= 47.0–71.0), was
55.9% female, included 19.7% Black and
12.8% Hispanic individuals, and had a mean
incomeof 113.4%of the federal poverty level.
The sample had a mean HEI score of 51.2
(IQR=40.4–61.0; on a scale from 0 to 100,
inwhich the latter indicates perfect adherence
to the 2015 Dietary Guidelines for Ameri-
cans).43 Additional characteristics are detailed
in Table 1.
Baseline Risk
The estimated median baseline 10-year
risk of the weighted, nationally representative
simulated sample was 8.5% for atherosclerotic
cardiovascular disease events (95% CI= 0.0,
43.1), 8.1% for incident diabetes (95%
CI= 5.0, 8.9), 2.4% for end-stage renal
disease among those with diabetes (95%
CI= 1.3, 8.8), 13.7% for neuropathy among
those with diabetes (95% CI= 2.4, 48.5),
8.0% for retinopathy among those with di-
abetes (95% CI= 2.1, 36.2), and 8.3% for
all-cause mortality (95% CI= 0.4, 46.9). The
corresponding life-course risk was 15.6% for
atherosclerotic cardiovascular disease events
(95% CI= 0.4, 56.0), 18.5% for incident di-
abetes (95% CI= 6.8, 29.6), 5.8% for end-
stage renal disease among those with diabetes
(95% CI= 1.3, 28.3), 26.4% for neuropathy
among those with diabetes (95% CI= 12.9,
66.3), and 16.4% for retinopathy among those
with diabetes (95% CI= 9.2, 45.9).
Postintervention Risk
For the cash intervention, we estimated a
reduction in the median 10-year risk of each
outcome to 8.2% for atherosclerotic cardio-
vascular disease events (95% CI= 0.0, 41.7),
7.3% for incident diabetes (95% CI= 4.2,
8.3), 2.4% for end-stage renal disease among
those with diabetes (95% CI= 1.3, 8.7),
13.5% for neuropathy among those with
diabetes (95% CI= 2.3, 47.9), 7.8% for
retinopathy among those with diabetes
(95% CI= 2.0, 34.6), and 7.8% for all-cause
mortality (95% CI= 0.3, 44.4). The corre-
sponding life-course risk reduced to 15.2% for
atherosclerotic cardiovascular disease events
(95% CI= 0.4, 54.5), 16.7% for incident di-
abetes (95% CI= 6.0, 26.5), 5.8% for end-
stage renal disease among those with diabetes
(95% CI= 1.3, 28.1), 26.0% for neuropathy
among those with diabetes (95% CI= 12.7,
65.6), and 15.9% for retinopathy among those
with diabetes (95% CI= 9.0, 44.7).
The reduction in risk from the cash in-
tervention would be expected to reduce the
number of atherosclerotic cardiovascular
disease events by 60.9 per 10 000 people
(95% CI= 58.0, 63.9), the number of in-
cident cases of type 2 diabetes mellitus by
117.5 per 10 000 (95%CI= 115.0, 120.3), the
number of cases of end-stage renal disease by
10.8 per 10 000 (95% CI= 5.9, 14.7), the
number of cases of diabetic neuropathy by
39.4 per 10 000 (95% CI= 31.4, 47.3), and
the number of cases of diabetic retinopathy by
41.1 per 10 000 (95% CI= 33.3, 48.6) over a
life-course time horizon (Figure 1).
For the CSA intervention estimated to
produce a 13% (95% CI= 9, 17) increase in
HEI score, we estimated a reduction in the
median 10-year risk of each outcome to 8.0%
for atherosclerotic cardiovascular disease
events (95% CI= 0.0, 40.8), 6.5% for inci-
dent diabetes (95% CI= 3.6, 7.7), 2.4% for
Reporting Standards checklist).13,37 We es-
timated DALYs averted over 10 years and 
over the life course by using health state utility 
values published in a previous comprehensive 
survey.38
The health care perspective included the
$300 per person per year intervention cost, 
plus a 16.7% ($50) overhead rate for the cash 
intervention and a 90.3% ($271) overhead 
rate for the CSA intervention, based on the 
trial experience. This overhead rate includes 
factors such as farm supplies, labor, and costs 
associated with administering the CSA and 
does not include costs associated with re-
search. In addition, we included health care 
costs per disease outcome, based on our 
estimates from the Optum Clinformatics 
Database of low-income US persons na-
tionwide, which included payments to health 
care providers, medications, and procedures, 
as well as out-of-pocket costs for patients both 
at the time of the event and each year of life 
thereafter. The societal perspective included 2 
additional costs: (1) economic benefits to the 
local economy39,40 and (2) lost work pro-
ductivity because of the health outcomes.41,42 
We modeled the economic benefits by using 
a “money multiplier” approach that accounts 
for both gains and losses. For example, be-
cause the money multiplier, with regard to 
the local economy, is greater for an additional
$1 spent at a small farm compared with a 
supermarket, our societal perspective esti-
mates account for both gains in business ex-
perienced by the farm and loss of business 
experienced by a supermarket.
For both the health care and societal 
perspectives, we computed the incremental 
cost-effectiveness ratio (ICER) as the change 
in dollars expended from baseline to the in-
tervention condition (cash or CSA) divided 
by the change in DALYs averted from 
baseline to the intervention condition. We 
discounted both costs and DALYs at a stan-
dard 3% annual rate.
Sensitivity Analyses
We performed 5 sets of sensitivity analyses. 
First, we simulated reduced levels of partic-
ipation from the baseline level of 100% par-
ticipation among eligible persons to identify 
the degree to which the ICER changed at 
varying participation levels. Second, we 
computed how much more effective at
(95% CI= 110.0, 117.0), the number of in-
cident cases of type 2 diabetes mellitus by
221.3 per 10 000 (95%CI= 218.2, 224.8), the
number of cases of end-stage renal disease by
18.3 per 10 000 (95% CI= 13.7, 22.2), the
number of cases of diabetic neuropathy by
72.8 per 10 000 (95% CI= 65.5, 79.8), and
the number of cases of diabetic retinopathy by
76.2 per 10 000 (95% CI= 67.6, 82.8) over a
life-course time horizon.
Cost-Effectiveness Analysis
Total discounted DALYs accumulated
over a 10-year policy horizon decreased from
8277 per 10 000 people (95% CI= 8195,
8366) at baseline to 7854 per 10 000 (95%
CI= 7768, 7950) under the cash intervention
and 7490 per 10 000 (95% CI= 7405, 7580)
under the CSA intervention (Table 2). In
both interventions, more DALYs were
averted through averted atherosclerotic car-
diovascular disease events than from the other
disease endpoints. Total discounted DALYs
accumulated over a life-course horizon de-
creased from 24 797 per 10 000 people (95%
CI= 24 584, 25 001) at baseline to 23 463 per
10 000 (95% CI= 23 241, 23 666) under the
cash intervention and 22 304 per 10 000 (95%
CI= 22 084, 22 510) under the CSA
intervention.
From a health care perspective, total dis-
counted health care costs (including in-
tervention costs) over 10 years increased from
$164.63 million (95% CI= $157.78 million,
$166.21 million) per 10 000 people to
$189.51 million (95% CI= $187.68 million,
$191.13 million) per 10 000 under the cash
intervention and $214.11 million (95%
CI= $212.27 million, $215.83 million) per
10 000 under the CSA intervention. In both
interventions, more health care dollars were
saved through averted cardiovascular disease
costs than from the other diseases. Total
discounted health care costs (including in-
tervention costs) over a life-course horizon
increased from $253.35 million (95%
CI= $251.55 million, $255.22 million) per
10 000 people over 10 years to $327.23
million (95% CI= $235.42 million, $329.04
million) per 10 000 under the cash inter-
vention and $389.64 million (95% CI=
$387.76, $391.53 million) per 10 000 under
the CSA intervention. From a health care
perspective, the interventions had an ICER
of $58 736 per DALY averted (95%
CI= $57 654, $60 007) for the cash inter-
vention and $62 864 per DALY averted (95%
CI= $62 300, $63 155) for the CSA inter-
vention over a 10-year time horizon, and
an ICER of $55 379 per DALY averted
(95% CI= $54 990, $55 291) for the cash
intervention and $54 661 per DALY averted
(95% CI= $54 473, $54 708) for the
CSA intervention over a life-course time
horizon.
From a societal perspective, incorporating
economic benefits of the interventions for the
agricultural sector and work productivity,
total discounted societal savings over 10 years
were $90.85 million (95% CI= $90.58 mil-
lion, $91.13 million) per 10 000 under the
cash intervention and $104.24 million (95%
CI= $103.98 million, $104.52 million) per
10 000 under the CSA intervention. Total
TABLE 1—Descriptive Statistics on the Study Sample: United States, National Health and
Nutrition Examination Survey, 2013–2016
Characteristic Mean (IQR) or %




Income, % of federal poverty level 113.4 (73.0–148.0)
Healthy Eating Index, score (0–100) 51.2 (40.4–61.0)
Body mass index, kg/m2 33.2 (28.1–36.2)
Systolic blood pressure, mm Hg 128.2 (116.0–138.0)
Total cholesterol, mg/dL 184.0 (156.0–207.0)
High-density lipoprotein cholesterol, mg/dL 50.4 (41.0–58.0)
Diabetes 39.3
Hemoglobin A1c 6.3 (5.5–6.5)
Serum creatinine, mg/dL 1.0 (0.7–1.0)
Urine microalbumin:creatinine ratio 105.0 (5.6–24.9)
Current tobacco smoker 21.8
Cardiovascular disease history 9.0




Note. IQR= interquartile range. Statistics describe properties of the unweighted National Health and
Nutrition Examination Survey Study (2013–2016) after applying the inclusion criteria of household
income less than 200% of the federal poverty level (according to US Department of Health and
Human Services guidelines for the year the data were collected) or enrollment in Medicaid health
insurance, and a body mass index of 25 kg/m2 or greater (n = 73 248).
end-stage renal disease among those with 
diabetes (95% CI = 1.3, 8.7), 13.4% for 
neuropathy among those with diabetes (95%
CI = 2.3, 47.2), 7.5% for retinopathy among 
those with diabetes (95% CI = 2.0, 33.4), and 
7.4% for all-cause mortality (95% CI = 0.3, 
42.1). The corresponding life-course risk 
reduced to 14.8% for atherosclerotic cardio-
vascular disease events (95% CI = 0.4, 53.2), 
14.9% for incident diabetes (95% CI = 5.3, 
24.2), 5.7% for end-stage renal disease among 
those with diabetes (95% CI = 1.3, 28.3), 
25.7% for neuropathy among those with 
diabetes (95% CI = 12.5, 64.8), and 15.5% for 
retinopathy among those with diabetes (95%
CI = 8.7, 43.4).
The reduction in risk from the CSA in-
tervention would be expected to reduce the 
number of atherosclerotic cardiovascular 
disease events by 113.4 per 10 000 people
$368.64 million (95% CI= $367.50 million,
$369.80 million) per 10 000 under the
CSA intervention. From a societal perspec-
tive, the interventions had a negative ICER,
implying cost savings, of –$155 719 per
DALY averted (95% CI= –$159 426,
–$154 583) for the cash intervention
and –$69 570 per DALY averted (95% CI=
–$69 865, –$69 360) for the CSA interven-
tion over a 10-year time horizon, with less
savings over this time horizon because of
higher overhead costs from the CSA. The
interventions had an ICER of –$191 100
per DALY averted (95% CI= –$191 767,
–$188 919) for the cash intervention
and –$93 182 per DALY averted (95%
CI= –$93 707, –$92 503) for the CSA
intervention over a life-course time
horizon.
Sensitivity Analyses
We found that the ICERs did not
change when varying participation levels,
as the fewer DALYs averted with lower
participation reduced proportionately to
dollars spent.
We found that the CSA intervention
would have to produce a 20% increase in HEI
score (95% CI= 16%, 24%), as compared
with its observed 13% increase, to achieve the
same ICER as the cash intervention from a
societal perspective over a life-course time
horizon, given the higher overhead rate of the
CSA intervention. By contrast, the CSA in-
tervention would have to cost $198 per
annum (95% CI= $170, $226) less, from a
baseline cost of $571, to have a similar societal
perspective life-course ICER as the cash in-
tervention. We estimated the ICER if
the intervention only produced behavior
change for the initial year of intervention,
followed by reversion to baseline prein-
tervention dietary quality (but still cost
the same amount into perpetuity, despite
losing effectiveness), the interventions
would have an ICER of $1.08 million per
DALY averted (95% CI= $939 909, $1.21
million) for the cash intervention and
$945 600 per DALY averted (95% CI=
$458 478, $1.42 million) for the CSA in-
tervention from a societal perspective over
a lifetime horizon.
The incremental cost-effectiveness
plane showing results of the probabilistic
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Notes. ASCVD= atherosclerotic cardiovascular disease events (myocardial infarctions and strokes); death = all-
cause mortality; DM inc = incident type 2 diabetes mellitus; ESRD=diabetes-related end-stage renal disease or
renal failure; Neuro = diabetes-related neuropathy; Retin =diabetes-related retinopathy. Boxplots display the
interquartile range (box), median (bold horizontal line), 1.5 times the interquartile range (whiskers), and outliers
(points).
FIGURE 1—Averted Disease Outcomes per 10000 People and Reduction in Disease
Outcomes From Cash and Community-Supported Agriculture (CSA) Interventions Over (a)
10-Year and (b) Life-Course Time Horizons: United States
discounted societal costs savings over a 
life-course horizon were $328.84 million
(95% CI = $327.65 million, $329.89 million) 
per 10 000 under the cash intervention and
Furthermore, we observed that from a societal
perspective both interventions would be
expected to produce net cost savings.
Notably, we refuted our a priori hypothesis
that the CSA intervention would be more
cost-effective than providing a cash-based
incentive alone. The CSA intervention
would have to increase its positive effects
on diet or reduce its costs to be similarly
cost-saving.
This study is consistent with and expands
previouswork that estimated the effectiveness
and cost-effectiveness of nutritional subsidies
in lower-income individuals. A previous
randomized study found improvements in
diet quality for a 30% subsidy on the purchase
of fruit and vegetables via the Supplemen-
tal Nutrition Assistance Program (SNAP),44
and previous modeling studies of this
type of intervention have estimated posi-
tive effects on health and health care
spending.45,46 A recent cost-effectiveness
analysis of economic incentive programs
offered throughMedicaid, Medicare, or both
found that these programs could be highly
cost-effective.47
This study adds to the literature by
modeling a different type of intervention—
one based in aCSA and that is not restricted to
SNAP participants. Instead, this type of in-
tervention could be offered through clinics or
as a health insurance benefit. Indeed, care
systems, payers, and employers are already
experimenting with such a benefit.48–50 An
interesting finding in this study was that while
both programs were cost-saving from a
TABLE 2—Cost-Effectiveness Analysis: United States
10-Year Life-Course
Baseline Cash CSA Baseline Cash CSA
DALYs accumulated, mean
(95% CI) per 10 000 population
Atherosclerotic cardiovascular
disease events
2 256 (2 244, 2 273) 2 138 (2 215, 2 158) 2 039 (2 027, 2 058) 6 469 (6 434, 6 511) 6 122 (6 083, 6 163) 5 829 (5 788, 5 871)
Incident diabetes 214 (205, 222) 179 (172, 188) 153 (145, 161) 1 344 (1 316, 1 374) 1 141 (1 115, 1 167) 972 (947, 992)
End-stage renal disease 512 (503, 522) 504 (493, 515) 495 (485, 505) 2 524 (2 498, 2 548) 2 431 (2 397, 2 455) 2 355 (2 322, 2 383)
Diabetic neuropathy 1 253 (1 237, 1 269) 1 181 (1 170, 1 197) 1 121 (1 107, 1 134) 4 428 (4 391, 4 459) 4 148 (4 112, 4 182) 3 907 (3 872, 3 937)
Diabetic retinopathy 957 (947, 968) 895 (883, 908) 845 (833, 855) 3 457 (3 420, 3 490) 3 217 (3 188, 3 345) 3 010 (2 980, 3 038)
All-cause mortality 3 085 (3 059, 3 112) 2 955 (2 925, 2 983) 2 837 (2 808, 2 868) 6 574 (6 526, 6 620) 6 404 (6 346, 6 454) 6 231 (3 872, 3 937)
Total 8 277 (8 195, 8 366) 7 854 (7 768, 7 950) 7 490 (7 405, 7 580) 24 797 (24 584, 25 001) 23 463 (23 241, 23 666) 22 304 (22 084, 22 510)
Health care costs (economic losses),




. . . 33.08 (33.07, 33.09) 53.79 (53.77, 53.80) . . . 88.94 (88.91, 88.98) 144.49 (144.38, 144.55)
Atherosclerotic cardiovascular
disease events
63.70 (63.29, 64.07) 59.93 (59.52, 60.30) 61.67 (61.29, 62.02) 87.98 (87.54, 88.38) 82.81 (82.46, 83.17) 85.20 (84.76, 85.60)
Incident diabetes 8.68 (8.57, 8.79) 6.87 (6.77, 6.96) 7.69 (7.61, 7.80) 15.68 (15.60, 15.78) 12.61 (12.52, 12.70) 14.05 (13.97, 14.14)
End-stage renal disease 42.84 (42.16, 43.54) 42.26 (41.34, 43.04) 42.64 (41.74, 43.50) 76.20 (75.32, 77.14) 73.14 (72.24, 74.05) 74.44 (73.54, 75.36)
Diabetic neuropathy 37.36 (37.10, 37.66) 36.10 (35.82, 36.37) 36.69 (36.35, 36.97) 55.04 (54.79, 44.32) 52.63 (52.33, 52.94) 53.74 (53.45, 54.06)
Diabetic retinopathy 12.05 (11.95, 12.14) 11.27 (11.16, 11.37) 11.63 (11.51, 11.73) 18.45 (18.30, 18.60) 17.08 (16.97, 17.20) 17.72 (17.60, 17.83)
Total 164.63 (157.78, 166.21) 189.51 (187.68, 191.13) 214.11 (212.27, 215.83) 253.35 (251.55, 255.22) 327.23 (235.42, 329.04) 389.64 (387.76, 391.53)
Societal savings (economic gains),
mean $ (95% CI) in millions per
10 000 population
Agricultural sector net profit gains . . . 40.26 (40.25, 40.28) 52.56 (52.54, 52.58) . . . 108.26 (108.21, 108.30) 141.20 (141.15, 141.26)
Disease-related economic
productivity gains
. . . 50.59 (50.34, 50.86) 51.68 (51.44, 51.94) . . . 220.58 (219.44, 221.59) 227.44 (226.36, 228.54)
Total . . . 90.85 (90.58, 91.13) 104.24 (103.98, 104.52) . . . 328.84 (327.65, 329.89) 368.64 (367.50, 369.80)
Note. CI = confidence interval; CSA = community-supported agriculture; DALYs = disability-adjusted life years. Discounted DALYs and costs, from a health care
and societal perspective, estimated under the baseline (preintervention), cash intervention, and CSA intervention scenarios over 10-y and life-course time
horizons. DALYs and costs were discounted at a 3% annual rate. The societal perspective includes cost savings attributable to increased agricultural economic
sector profits and workplace productivity attributable to lower disease events.
DISCUSSION
Combining data from a community-based 
randomized trial of cash and CSA interven-
tions with national surveys, we developed 
and implemented a microsimulation model 
to assess the potential impact and cost-
effectiveness of improving dietary quality on 
cardiovascular disease and type 2 diabetes 
outcomes among low-income US adults. 
We observed that from a health care spend-
ing perspective, both interventions would 
be expected to have incremental cost-
effectiveness ratios less than $100 000 per 
DALY averted, with the cash intervention 
being more cost-effective in the short term 
(10-year time horizon) but the CSA inter-
vention having equivalent cost-effectiveness 
in the long run (life-course time horizon).
work relating changes in diet to other inter-
ventions or different variations of the strategies
studied (e.g., higher or low subsidy values)
becomes available, it would make sense to in-
clude additional interventions to the set studied.
The results of this study suggest several
directions for future work. First, it is im-
portant to replicate trial results in different
contexts to enhance generalizability. Next,
given that there now appear to be multiple
cost-effective interventions for improving
diet quality in low-income populations, itwill
be important to investigate how to best de-
ploy such policies to maximize population
health impact. Given the complexity of so-
cioeconomic disparities in diet-related illness,
there are likely to be no “silver bullets.” In-
stead, a combination of programs with dif-
ferent eligibility criteria, benefit levels, and
interventional approaches will likely be
needed. Better understanding for whom a
given program ismost beneficial, and how one
program might interact with others, will help
inform public policy for improving health.
Overall, our simulation study suggests that
both an unconditional cash transfer andCSA-
based interventions may be cost-effective
for improving diets among low-income
persons in the United States. These programs
may generate health improvements, agricul-
tural economic benefits, productivity gains,
and ultimately societal cost-savings.
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